Aim Autoimmune thyroid disease (AITD) is a multifactorial disease with a genetic predisposition. The protein tyrosine phosphatase-22 (PTPN-22) gene is a powerful inhibitor of T-cell activation. The aim of this study was to compare messenger RNA (mRNA) PTPN22 expression between healthy persons and patients with hypothyroidism and with their affected relatives. Methods This was a cross-sectional, prospective and descriptive study. DNA was extracted from leukocytes (4,000-10,000 cells) using the Magna Pure LC 2.0 Instrument and MagNA Pure LC RNA Isolation Kit I (Roche, Germany). A real-time polymerase reaction (qPCR) was performed utilizing the primer sets specific for the PTPN-22 gene, and the succinate dehydrogenase complex, the subunit A, Flavoprotein (Fp) (SDHA) constitutive gene. All reactions were performed with the 7500 Fast Real Time PCR System (Applied Biosystems, Applera International, Inc. Cheshire, UK) employing the SYBR Advantage qPCR Premix Kit (Clontech, USA). Results Twenty five patients with AITD (hypothyroidism), all females (mean age 39.6 ± 11.8 years) and 23 control subjects (mean age 24.4 ± 4.2 years) were included in the study. There was no statistical difference between both groups in PTPN-22 mRNA expression (p = 0.125). Conclusion There is no clear difference in mRNA PTPN-22 expression. The ideal genes for a systematic screening for familial AITD are yet to be found.
Saravanan P, Dayan C. Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001. p. 315–37.
2.
Cappa M, Bizzarri C, Crea F. Autoimmune thyroid diseases in children. J Thyroid Res. 2010. p. 675703.
3.
Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res. 2012. p. 204–13.
4.
Jacobson E, Tomer Y. CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun. 2007. p. 85–98.
5.
Zerón M, Tiroidopatía Autoinmune H. Estudiantes de Medicina Pro Investigación y I Encuentro Nacional Semilleros de la Investigación. 6 de mayo 2011.
6.
Ban Y, Greenberg D, Concepción E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A. 2003. p. 15119–24.
7.
Yin X, Latif R, Bahn R, Tomer Y, Davies T. Influence of the TSH receptor gene on susceptibility to Graves’ disease and Graves’ ophthalmopathy. Thyroid. 2008. p. 1201–6.
8.
Du L, Yang J, Huang J, Ma Y, Wang H, Xiong T, et al. The associations between the polymorphisms in the CTLA-4 gene and the risk of Graves’ disease in the Chinese population. BMC Med Genet. 2013. p. 46.
9.
Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto’s thyroiditis or Addison’s disease in the German population. Eur J Endocrinol. 2005. p. 47–58.
10.
Ban Y, Davies T, Greenberg D, Concepcion E, Osman R, Oashi T, et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves’ disease. Genes Immun. 2004. p. 203–8.
11.
Ban Y, Greenberg D, Davies T, Jacobson E, Concepcion E, Tomer Y. Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. J Clin Endocrinol Metab. 2008. p. 3589–96.
12.
Ban Y, Tozaki T, Taniyama M, Tomita M. The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase-22 gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese. Thyroid. 2005. p. 1115–8.
13.
Douroudis K, Prans E, Haller K, Nemvalts V, Rajasalu T, Tillmann V, et al. Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens. 2008. p. 425–30.
14.
Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths C, et al. Worthington J. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005. p. 1694–9.
15.
Piotrowski P, Lianeri M, Wudarski M, Lacki J. Jagodzinski PP. Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland. Clin Exp Rheumatol. 2008. p. 1099–102.
16.
Criswell L, Pfeiffer K, Lum R, Gonzales B, Novitzke J, Kern M, et al. Gregersen PK. Analysis of Families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) Collection: the PTPN22 620W Allele Associates with Multiple Autoimmune Phenotypes. Am J Hum Genet. 2005. p. 561–71.
17.
Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. Lymphoid tyrosine phosphatase (PTPN22/ LYP) variant and Graves’ disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol. 2005. p. 679–82.
18.
Skinningsrud B, Husebye E, Gervin K, Løvås K, Blomhoff A, Wolff A, et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. Eur J Hum Genet. 2008. p. 977–82.
19.
Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais J, Eymard B, et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol. 2006. p. 404–7.
20.
Dayan C, Daniels G. Chronic autoimmune thyroiditis. N Engl J Med. 1996. p. 99–107.
21.
Díaz-Gallo L, Gourh P, Broen J, Simeon C, Fonollosa V, Ortego-Centeno N, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis. 2011. p. 454–62.
22.
Viken M, Amundsen S, Kvien T, Boberg K, Gilboe I, Lilleby V, et al. Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun. 2005. p. 271–3.
23.
Prentice L, Phillips D, Sarsero D, Beever K, Mc-Lachlan S, Smith B. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol. 1990. p. 493–8.
24.
Burn G, Svensson L, Sanchez-Blanco C, Saini M, Cope A. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 2011. p. 3689–98.
25.
Mcgrogan A, Seaman H, Wright J, De Vries C. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol. 2008. p. 687–96.
26.
Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013. p. 646–53.
27.
Cooper D, Biondi B. Subclinical thyroid disease. Lancet. 2012. p. 1142–54.
28.
Inoue N, Watanabe M, Yamada H, Takemura K, Hayashi F, Yamakawa N, et al. Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes. J Clin Immunol. 2012. p. 1243–52.
29.
Ichimura M, Kaku H, Fukutani T, Koga H, Mukai T, Miyake I, et al. Associations of Protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves’ disease in a Japanese population. Thyroid. 2008. p. 625–30.
30.
Wiersinga W. Thyroid autoimmunity. Endocr Dev. 2014. p. 139–57.
31.
Balazs C. The role of hereditary and environmental factors in autoimmune thyroid diseases. Orv Hetil. 2012. p. 1013–22.
32.
Effraimidis G, Wiersinga W. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014. p. 241-R252.
33.
Le Rouzic A. Estimating directional epistasis. Front Genet. 2014. p. 198.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
